FDA approves painkiller said to thwart addiction
Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
What happened
The Food and Drug Administration Thursday approved a new class of pain pill that is not addictive like opioids. Suzetrigine, being sold as Journavx by Vertex Pharmaceuticals, is the first new pharmaceutical treatment for pain to win FDA approval in more than 20 years.
Who said what
Opioids work by binding to receptors in the brain that receive pain signals from nerves around the body, but "those chemical interactions also give rise to opioids' addictive effects," The Associated Press said. But while prescription opioids have helped fuel an epidemic of addiction and overdoses, suzetrigine "works differently," intercepting pain signals before they reach the brain.
In two clinical trials submitted by Vertex, suzetrigine was more effective than a placebo at treating short-term pain in people recovering from stomach and foot surgery, and on par with a combined acetaminophen-hydrocodone pill, like Vicodin.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
What next?
Journavx was approved to treat acute pain in adults. But at a list price of $15.50 a pill, it "faces some hurdles in winning over physicians, hospitals and insurance companies," The Washington Post said. The new painkiller is promising because "there are a number of people who, once they have an opioid, want an opioid constantly," University of Washington pain expert Dr. John Loeser said to The New York Times. But acetaminophen-opioid pills are "dirt cheap."
-
Political cartoons for January 11Cartoons Sunday’s political cartoons include green energy, a simple plan, and more
-
The launch of the world’s first weight-loss pillSpeed Read Novo Nordisk and Eli Lilly have been racing to release the first GLP-1 pill
-
Maduro’s capture: two hours that shook the worldTalking Point Evoking memories of the US assault on Panama in 1989, the manoeuvre is being described as the fastest regime change in history
-
Trump HHS slashes advised child vaccinationsSpeed Read In a widely condemned move, the CDC will now recommend that children get vaccinated against 11 communicable diseases, not 17
-
Deaths of children under 5 have gone up for the first time this centuryUnder the radar Poor funding is the culprit
-
A fentanyl vaccine may be on the horizonUnder the radar Taking a serious jab at the opioid epidemic
-
Health: Will Kennedy dismantle U.S. immunization policy?Feature ‘America’s vaccine playbook is being rewritten by people who don’t believe in them’
-
Nitazene is quietly increasing opioid deathsThe explainer The drug is usually consumed accidentally
-
More adults are dying before the age of 65Under the radar The phenomenon is more pronounced in Black and low-income populations
-
Ultra-processed AmericaFeature Highly processed foods make up most of our diet. Is that so bad?
-
Climate change is getting under our skinUnder the radar Skin conditions are worsening because of warming temperatures
